For research use only. Not for therapeutic Use.
HCV-IN-31 (compound 4) is a HCV inhibitor, with an EC50/EC95 of 15.7 μM for HCV replicon[1].
| Catalog Number | I044641 |
| CAS Number | 1998705-62-6 |
| Synonyms | (2R,3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-2-(hydroxymethyl)-4-methyloxolan-3-ol |
| Molecular Formula | C12H17FN6O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C12H17FN6O3/c1-12(13)7(21)5(3-20)22-10(12)19-4-16-6-8(15-2)17-11(14)18-9(6)19/h4-5,7,10,20-21H,3H2,1-2H3,(H3,14,15,17,18)/t5-,7-,10-,12-/m1/s1 |
| InChIKey | HPINXBYYNVDDEB-GSWPYSDESA-N |
| SMILES | CC1(C(C(OC1N2C=NC3=C(N=C(N=C32)N)NC)CO)O)F |
| Reference | [1]. Jean-Pierre Sommadossi, et al. BETA-D-2-DEOXY-2-ALPHA-FLUORO-2- BETA-C-SUBSTITUTED-2-MODIFIED N6-SUBSTITUTED PURINE NUCLEOTDES FORHCV TREATMENT. US20160257706A1. |
